{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:19:26Z","timestamp":1787721566726,"version":"build-2784847793"},"reference-count":37,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Current Research Funds 2026"],"award-info":[{"award-number":["Current Research Funds 2026"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"award":["Current Research Funds 2026"],"award-info":[{"award-number":["Current Research Funds 2026"]}],"id":[{"id":"https:\/\/ror.org\/00789fa95","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background: Migraine is a leading cause of disability worldwide and is frequently associated with psychiatric comorbidities that may influence pain perception and treatment response. Anti-CGRP monoclonal antibodies represent an effective preventive treatment, although response variability remains poorly understood, particularly in patients with complex neuropsychiatric profiles. Case Presentation: We report the case of a 49-year-old woman with migraine with a previously chronic course and psychiatric comorbidity, including bipolar disorder and obsessive\u2013compulsive disorder, treated with galcanezumab. The clinical course was characterized by an \u201con-off-on\u201d pattern, with marked worsening after treatment discontinuation and subsequent improvement after treatment reintroduction. Results: The patient presented with severe emotional distress (BDI-II = 59; STAI = 77\u201380), a very high self-reported burden of central sensitization-related symptoms (CSI = 100\/100) and reduced performance on cognitive screening measures (MoCA = 19\/30; BCSE = 18\/58). MMPI-3 findings indicated a high level of self-reported psychological distress; however, substantial elevations in symptom-validity indicators required cautious interpretation of the substantive scales. Conclusions: This case illustrates that complex neuropsychiatric comorbidity and psychotropic polypharmacotherapy did not preclude an apparent clinical benefit from galcanezumab. Treatment discontinuation and reintroduction were temporally associated with worsening and subsequent improvement in headache frequency, although causality cannot be established from a single uncontrolled observation. The case also highlights the potential value of coordinated neurological and psychiatric monitoring in patients with migraine and complex neuropsychiatric profiles.<\/jats:p>","DOI":"10.3390\/jcm15176540","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:49:34Z","timestamp":1787582974000},"page":"6540","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Response to Galcanezumab in a Patient with Complex Neuropsychiatric Comorbidity: A Case Report"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8665-3575","authenticated-orcid":false,"given":"Anna","family":"Anselmo","sequence":"first","affiliation":[{"name":"IRCCS Centro Neurolesi Bonino-Pulejo, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0978-605X","authenticated-orcid":false,"given":"Maria","family":"Pagano","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi Bonino-Pulejo, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4862-3832","authenticated-orcid":false,"given":"Francesco","family":"Corallo","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi Bonino-Pulejo, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3984-2331","authenticated-orcid":false,"given":"Irene","family":"Cappadona","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi Bonino-Pulejo, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9700-2157","authenticated-orcid":false,"given":"Rosario","family":"Grugno","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi Bonino-Pulejo, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Cosenza","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi Bonino-Pulejo, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Vita","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi Bonino-Pulejo, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Lo Presti","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi Bonino-Pulejo, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2052-0970","authenticated-orcid":false,"given":"Davide","family":"Cardile","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi Bonino-Pulejo, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Lo Buono","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi Bonino-Pulejo, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8566-3166","authenticated-orcid":false,"given":"Rocco Salvatore","family":"Calabr\u00f2","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi Bonino-Pulejo, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1007\/s00415-012-6725-x","article-title":"Psychiatric comorbidities of episodic and chronic migraine","volume":"260","author":"Buse","year":"2013","journal-title":"J. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1136\/jnnp-2015-312233","article-title":"Migraine and its psychiatric comorbidities","volume":"87","author":"Minen","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1152\/physrev.00034.2015","article-title":"Pathophysiology of Migraine: A Disorder of Sensory Processing","volume":"97","author":"Goadsby","year":"2017","journal-title":"Physiol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.pain.2010.09.030","article-title":"Central sensitization: Implications for the diagnosis and treatment of pain","volume":"152","author":"Woolf","year":"2011","journal-title":"Pain"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Pavelic, A.R., W\u00f6ber, C., Riederer, F., and Zebenholzer, K. (2022). Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data. Cells, 12.","DOI":"10.20944\/preprints202211.0177.v1"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/WCO.0000000000000309","article-title":"Understanding migraine and psychiatric comorbidity","volume":"29","author":"Seng","year":"2016","journal-title":"Curr. Opin. Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Sanabria-Gago, C., L\u00e1zaro, I.F., Heredia, P., S\u00e1nchez-Soblechero, A., Ros, A.L., Buzo, E.L., Osorio, Y.G., Guerrero-Peral, \u00c1., Gonzalez-Martinez, A., and Azor\u00edn, D.G. (2025). SAFE-CGRP study: Multicenter retrospective evaluation of the safety of CGRP pathway-targeting monoclonal antibodies in migraine with relevant comorbidities or conditions excluded from trials. Front. Neurol., 16.","DOI":"10.3389\/fneur.2025.1703876"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/B978-0-12-823357-3.00013-6","article-title":"Psychiatric comorbidities of migraine","volume":"199","author":"McCracken","year":"2024","journal-title":"Handb. Clin. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1530-7085.2003.03034.x","article-title":"The numeric rating scale for clinical pain measurement: A ratio measure?","volume":"3","author":"Hartrick","year":"2003","journal-title":"Pain Pract."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jpain.2012.11.012","article-title":"The Central Sensitization Inventory (CSI): Establishing clinically significant values for identifying central sensitivity syndromes in an outpatient chronic pain sample","volume":"14","author":"Neblett","year":"2013","journal-title":"J. Pain"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/arclin\/acv037","article-title":"The Brief Cognitive Status Examination (BCSE): Comparing Diagnostic Utility and Equating Scores to the Mini-Mental State Examination (MMSE)","volume":"30","author":"Hilsabeck","year":"2015","journal-title":"Arch. Clin. Neuropsychol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1037\/pas0000969","article-title":"Psychometric properties of the Minnesota Multiphasic Personality Inventory-3 (MMPI-3) in a clinical neuropsychology setting","volume":"33","author":"Whitman","year":"2021","journal-title":"Psychol. Assess."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Graffigna, G., Barello, S., Bonanomi, A., and Lozza, E. (2015). Measuring patient engagement: Development and psychometric properties of the Patient Health Engagement (PHE) Scale. Front. Psychol., 6.","DOI":"10.3389\/fpsyg.2015.00274"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"682503","DOI":"10.1155\/2015\/682503","article-title":"Self-Assessment of Adherence to Medication: A Case Study in Campania Region Community-Dwelling Population","volume":"2015","author":"Menditto","year":"2015","journal-title":"J. Aging Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1590\/1516-4446-2012-1048","article-title":"Psychometric properties of the Beck Depression Inventory-II: A comprehensive review","volume":"35","author":"Wang","year":"2013","journal-title":"Braz. J. Psychiatry"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1007\/s40520-021-01815-0","article-title":"Psychometric properties of the STAI-Y scales and normative data in an Italian elderly population","volume":"33","author":"Ilardi","year":"2021","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial","volume":"75","author":"Stauffer","year":"2018","journal-title":"JAMA Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s10194-021-01363-y","article-title":"Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: An observational longitudinal cohort study","volume":"22","author":"Vernieri","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/14728222.2020.1724285","article-title":"Calcitonin gene-related peptide (CGRP): Role in migraine pathophysiology and therapeutic targeting","volume":"24","author":"Wattiez","year":"2020","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Altamura, C., Corbelli, I., de Tommaso, M., Di Lorenzo, C., Di Lorenzo, G., Di Renzo, A., Filippi, M., Jannini, T.B., Messina, R., and Parisi, P. (2021). Pathophysiological bases of comorbidity in migraine. Front. Hum. Neurosci., 15.","DOI":"10.3389\/fnhum.2021.640574"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"21824","DOI":"10.1038\/s41598-024-72282-6","article-title":"Efficacy of galcanezumab in migraine central sensitization","volume":"14","author":"Danno","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.medcli.2022.09.023","article-title":"Effectiveness of anti-CGRP monoclonal antibodies in the preventive treatment of migraine: A prospective study of 63 patients. Efectividad de anticuerpos monoclonales anti-PRGC en el tratamiento preventivo de la migra\u00f1a: Estudio prospectivo de 63 pacientes","volume":"160","author":"Castrillo","year":"2023","journal-title":"Med. Clin."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.2147\/JPR.S329280","article-title":"Central Sensitization in Migraine: A Narrative Review","volume":"15","author":"Suzuki","year":"2022","journal-title":"J. Pain Res."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Duan, S., Ren, Z., Xia, H., Wang, Z., Zheng, T., Li, G., Liu, L., and Liu, Z. (2023). Associations between anxiety, depression with migraine, and migraine-related burdens. Front. Neurol., 14.","DOI":"10.3389\/fneur.2023.1090878"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s10194-024-01923-y","article-title":"Migraine and cognitive dysfunction: A narrative review","volume":"25","author":"Fernandes","year":"2024","journal-title":"J. Headache Pain"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e208109","DOI":"10.1212\/WNL.0000000000208109","article-title":"Neuropsychological Function in Migraine Headaches: An Expanded Comprehensive Multidomain Meta-Analysis","volume":"102","author":"Pizer","year":"2024","journal-title":"Neurology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00415-026-13672-w","article-title":"Investigating the impact of migraine on short-term and working memory: A systematic review and meta-analysis","volume":"273","author":"McKay","year":"2026","journal-title":"J. Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s10194-022-01462-4","article-title":"Association between migraine and cognitive impairment","volume":"23","author":"Gu","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_31","first-page":"173","article-title":"Pain and Psychology-A Reciprocal Relationship","volume":"17","author":"Vadivelu","year":"2017","journal-title":"Ochsner J."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Cardona-Roca, L., Segu\u00ed-Solanes, C., Cano-Alonso, M., Sosa-Pons, A., Almendros-Abad, N., and Sola, N.R. (2025). Impact of anti-CGRP monoclonal antibodies on treatment satisfaction and quality of life in patients with resistant migraine: A retrospective real-world study. BMC Neurol., 25.","DOI":"10.1186\/s12883-025-04384-1"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3331024251335927","DOI":"10.1177\/03331024251335927","article-title":"Effectiveness and tolerability of atogepant in the prevention of migraine: A real life, prospective, multicentric study (the STAR study)","volume":"45","author":"Vernieri","year":"2025","journal-title":"Cephalalgia Int. J. Headache"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Mechtler, L., Saikali, N., McVige, J., Hughes, O., Traut, A., and Adams, A.M. (2022). Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine. Front. Neurol., 12.","DOI":"10.3389\/fneur.2021.788159"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s10194-019-0988-x","article-title":"Understanding the nature of psychiatric comorbidity in migraine: A systematic review focused on interactions and treatment implications","volume":"20","author":"Dresler","year":"2019","journal-title":"J. Headache Pain"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e735","DOI":"10.1002\/hsr2.735","article-title":"Patient activation for self-management among adult patients with multimorbidity in primary healthcare settings","volume":"5","author":"Paukkonen","year":"2022","journal-title":"Health Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Klepper, J.E., Moran, H., and Newman, L. (2026). Exploring the relationship between migraine and mental health\u2014Perspectives from the patient and physician experience. Front. Neurol., 17.","DOI":"10.3389\/fneur.2026.1773577"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6540\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:20:22Z","timestamp":1787718022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":37,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15176540"],"URL":"https:\/\/doi.org\/10.3390\/jcm15176540","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]}}}